Typhoid Fever Vaccine in South Korea Trends and Forecast
The future of the typhoid fever vaccine market in South Korea looks promising with opportunities in the hospital & clinic and specialty center markets. The global typhoid fever vaccine market is expected to reach an estimated $1.0 billion by 2030 with a CAGR of 14.5% from 2024 to 2030. The typhoid fever vaccine market in South Korea is also forecasted to witness strong growth over the forecast period. The major drivers for this market are the rise in the prevalence of typhoid and the growing demand for combined vaccines that offer protection against multiple diseases.
• Lucintel forecasts that, within the type category, capsular polysaccharide is expected to witness the highest growth over the forecast period due to its efficiency at preventing infection from bacteria, being safe with limited side effects, and it can be administered orally or by injection, making it easy and convenient to use.
• Within the end use category, hospitals & clinics are expected to witness the highest growth over the forecast period.
Emerging Trends in the Typhoid Fever Vaccine Market in South Korea
The typhoid fever vaccine market in South Korea is experiencing significant advancements driven by technological innovation, government support, and international collaboration. Although typhoid fever is not endemic in South Korea, the country robust pharmaceutical industry and proactive public health policies have positioned it as a key player in vaccine development and distribution. Emerging trends include the development of advanced vaccines, strategic partnerships, and a focus on global health initiatives. These developments are reshaping the landscape of typhoid fever prevention and contributing to global efforts to combat the disease.
• Development of Typhoid Conjugate Vaccines (TCVs): South Korean pharmaceutical companies are actively involved in developing Typhoid Conjugate Vaccines (TCVs). For instance, SK Bioscience, in collaboration with the International Vaccine Institute (IVI), developed SKYTyphoid™, which achieved World Health Organization prequalification in February 2024. This milestone enables the vaccine procurement by UN agencies and its distribution in typhoid-endemic regions, highlighting South Korea contribution to global health.
• Expansion of Vaccine Manufacturing Capabilities: South Korea is investing in expanding its vaccine manufacturing infrastructure to meet both domestic and international demand. The country advanced biotechnology sector provides a robust foundation for vaccine development, contributing to the growth of the vaccine market.
• Government Support for Vaccine Development and Export: The South Korean government actively supports vaccine research and development through funding and policy initiatives. This support has bolstered the country vaccine industry, enabling it to expand its global presence. Government backing has been instrumental in facilitating international collaborations and enhancing the competitiveness of South Korean vaccines in the global market.
• Introduction of Oral Typhoid Vaccines: In March 2020, Daewoong Pharmaceutical launched Vivotif, an oral typhoid fever vaccine, in the South Korean market. This introduction provides a convenient alternative to injectable vaccines, potentially increasing vaccination rates among travelers and others at risk. The availability of oral vaccines reflects a trend towards diversifying vaccine options to meet varying patient needs.
• International Collaboration and Global Health Initiatives: South Korean vaccine manufacturers are engaging in international collaborations to address global health challenges. Partnerships with organizations like IVI and funding from entities such as the Bill & Melinda Gates Foundation have facilitated the development of vaccines targeting diseases prevalent in low- and middle-income countries. These collaborations enhance South Korea role in global health and contribute to the worldwide fight against typhoid fever.
In conclusion, South Korea typhoid fever vaccine market is being transformed by the development of advanced vaccines, expansion of manufacturing capabilities, government support, introduction of oral vaccine options, and international collaborations. These trends not only strengthen South Korea position in the global vaccine industry but also contribute significantly to international efforts to prevent and control typhoid fever.
Recent Developments in the Typhoid Fever Vaccine Market in South Korea
Typhoid fever, caused by Salmonella enterica serovar Typhi, remains a public health concern in various regions. In South Korea, recent advancements in vaccine development and international collaborations have significantly influenced the typhoid vaccine market. These developments aim to enhance vaccine efficacy, accessibility, and global distribution, thereby contributing to improved disease prevention strategies.
• Development of SKYTyphoid™: SK Bioscience, in collaboration with the International Vaccine Institute (IVI), developed SKYTyphoid™, a typhoid conjugate vaccine utilizing conjugate vaccine production technology. This partnership, initiated in 2013, focused on creating a vaccine that offers long-term protection with a single dose, suitable for individuals aged six months and older. The development of SKYTyphoid™ underscores South Korea commitment to advancing vaccine technology and addressing global health challenges.
• Licensure for Export by Korean Ministry of Food and Drug Safety: In May 2022, SKYTyphoid™ received an export license from the Korean Ministry of Food and Drug Safety. This approval marked a significant milestone, enabling SK Bioscience to distribute the vaccine internationally. The licensure reflects the vaccine compliance with stringent safety and efficacy standards, facilitating its availability in countries burdened by typhoid fever.
• World Health Organization Prequalification: In February 2024, SKYTyphoid™ achieved prequalification from the World Health Organization (WHO). This designation certifies the vaccine quality, safety, and efficacy, allowing its procurement by United Nations agencies and endorsement for use in global immunization programs. WHO prequalification enhances the vaccine credibility and paves the way for its inclusion in public health initiatives worldwide.
• Global Distribution Initiatives: Following WHO prequalification, SK bioscience announced plans to supply SKYTyphoid™ to low- and middle-income countries through public procurement markets. This initiative aims to address the high demand for typhoid vaccines in endemic regions, contributing to global efforts to control and prevent typhoid fever. South Korea role in manufacturing and distributing the vaccine underscores its contribution to global health equity.
• Ongoing Research and Development: South Korea continues to invest in vaccine research and development, focusing on innovative approaches to enhance vaccine efficacy and accessibility. Collaborations between institutions like IVI and biotechnology companies aim to develop next-generation vaccines, addressing emerging health challenges and reinforcing the country position in the global vaccine market.
In summary, South Korea advancements in developing and distributing SKYTyphoid™ have significantly impacted the typhoid vaccine market. Through successful collaborations, regulatory approvals, and a commitment to global health, South Korea has enhanced vaccine accessibility and contributed to international efforts to combat typhoid fever.
Strategic Growth Opportunities for Typhoid Fever Vaccine Market in South Korea
The typhoid fever vaccine market in South Korea is expanding due to increased global travel, military deployment, and government initiatives focused on disease prevention. While South Korea has a strong healthcare system, typhoid remains a concern for travelers, food industry workers, and military personnel. Strengthening vaccination programs through public-private partnerships, school-based initiatives, and mandatory immunization for high-risk groups will drive market growth. Advancements in vaccine technology and digital health records will further enhance accessibility and compliance, creating sustainable opportunities for vaccine manufacturers and healthcare providers in South Korea.
• Pre-Travel Vaccination for Outbound Travelers: South Korea has a high volume of outbound travelers, particularly to typhoid-endemic regions in Southeast Asia and South Asia. Implementing mandatory or strongly recommended typhoid vaccinations for travelers can drive demand. Travel clinics, airport health centers, and digital health platforms can streamline vaccine distribution. Government incentives, such as subsidies for travelers visiting high-risk areas, can improve vaccine uptake. Collaboration with airlines, travel agencies, and healthcare providers to offer bundled vaccination services can further increase accessibility. Strengthening pre-travel health regulations will contribute to long-term growth in the typhoid vaccine market.
•Military and Peacekeeping Forces Immunization: South Korea’s military personnel, particularly those deployed in overseas missions or stationed in typhoid-endemic regions, are at higher risk of infection. Implementing routine typhoid vaccination as part of pre-deployment health screenings can significantly reduce disease incidence. Government contracts with vaccine manufacturers can ensure a stable supply at competitive pricing. Integrating typhoid vaccines into broader military immunization programs will improve efficiency. Digital health records can track vaccination status and ensure compliance. Strengthening immunization protocols for military personnel will not only protect the armed forces but also contribute to the overall expansion of the typhoid vaccine market.
•Mandatory Vaccination for Food Industry Workers: The food industry is a critical sector where typhoid transmission poses significant risks. Mandating typhoid vaccinations for food handlers in restaurants, street markets, and food processing facilities can minimize outbreaks and enhance food safety. Employer-sponsored vaccination programs and tax incentives for businesses complying with immunization requirements can boost vaccine uptake. Strengthening food safety regulations to include immunization as part of health certifications can drive demand. Public awareness campaigns highlighting the importance of typhoid vaccination in preventing foodborne diseases will further reinforce compliance, benefiting both public health and the vaccine market.
•School-Based Vaccination Programs: School-aged children are susceptible to typhoid fever, making educational institutions an ideal setting for vaccination campaigns. Integrating typhoid vaccines into routine school immunization programs can improve coverage rates. Government funding for free or subsidized school vaccinations can enhance accessibility, particularly for underserved communities. Collaboration between health authorities and schools to conduct on-site vaccination drives will streamline distribution. Digital vaccination tracking can ensure timely booster doses and monitor overall coverage. Raising awareness among students and parents about the importance of typhoid prevention through vaccination will contribute to long-term market sustainability.
•Advancements in Typhoid Vaccine Development and Distribution: South Korea’s strong biopharmaceutical sector presents opportunities for developing and producing advanced typhoid vaccines. Investment in research and development (R&D) for conjugate vaccines with longer-lasting immunity can drive market growth. Expanding domestic production will reduce dependence on imports and enhance supply chain resilience. Strengthening partnerships with global health organizations and expanding exports of typhoid vaccines to other markets will further increase revenue potential. Implementing digital health platforms for vaccine distribution and tracking can improve efficiency and accessibility, ensuring wider adoption among target populations.
The typhoid fever vaccine market in South Korea is set to grow through strategic initiatives targeting high-risk populations, including travelers, military personnel, food handlers, and students. Government policies, private-sector collaborations, and advancements in vaccine technology will drive adoption and accessibility. Strengthening immunization programs will not only enhance public health but also create sustainable opportunities for vaccine manufacturers and healthcare providers, positioning South Korea as a key player in the global typhoid vaccine market.
Typhoid Fever Vaccine Market in South Korea Driver and Challenges
The typhoid fever vaccine market in South Korea is influenced by various technological, economic, and regulatory factors. Advancements in vaccine development, strong healthcare infrastructure, and government support for immunization programs drive market growth. Increased international travel and awareness of vaccine-preventable diseases also contribute to rising demand. However, regulatory barriers, limited disease prevalence, and economic concerns pose challenges. Understanding these factors is essential for stakeholders, including healthcare providers, policymakers, and pharmaceutical companies, to develop strategies that ensure better vaccine accessibility and adoption. Addressing both drivers and challenges will help strengthen typhoid fever prevention efforts in South Korea.
The factors responsible for driving the typhoid fever vaccine market in South Korea include:
• Strong Healthcare Infrastructure and Access to Vaccines: South Korea has a well-developed healthcare system that ensures easy access to vaccines through hospitals, clinics, and pharmacies. Advanced medical facilities and efficient healthcare delivery systems enable widespread immunization coverage. Digital healthcare platforms further streamline vaccine distribution and appointment scheduling. The government invests in public health initiatives to maintain high vaccination rates, ensuring strong market demand. Improved healthcare accessibility enhances disease prevention efforts, reducing the risk of typhoid fever outbreaks. As the country continues to expand healthcare services, vaccine availability is expected to increase, driving further market growth.
• Government Immunization Policies and Public Health Initiatives: The South Korean government actively promotes immunization programs to prevent infectious diseases, including typhoid fever. National vaccination guidelines ensure high immunization coverage, particularly for high-risk groups such as travelers and military personnel. Government support in vaccine procurement and distribution strengthens market stability. Public health campaigns emphasize the importance of immunization, increasing public trust in vaccines. Collaboration with global health organizations ensures vaccine availability during disease outbreaks. Continued government commitment to immunization policies will support market expansion and improve typhoid fever prevention efforts across the country.
• Increasing International Travel and Risk of Imported Cases: South Korea experiences high levels of international travel for business, tourism, and education. Travelers visiting typhoid-endemic regions require vaccination, driving demand for typhoid fever vaccines. Public health authorities recommend vaccination for individuals traveling to high-risk areas, ensuring market stability. The risk of imported cases highlights the importance of pre-travel immunization, reinforcing the need for easily accessible vaccines. As global mobility increases, demand for travel-related vaccines is expected to grow. Strengthening pre-travel vaccination programs will help reduce disease transmission and support long-term market expansion.
• Advancements in Vaccine Technology and Research: South Korea invests in research and development to improve vaccine efficacy and accessibility. Innovations in conjugate vaccines provide long-term immunity, reducing the need for booster doses. Collaborations between pharmaceutical companies and research institutions enhance vaccine development efforts. Biopharmaceutical advancements ensure improved production processes, reducing costs and increasing supply. Ongoing research focuses on enhancing vaccine stability and effectiveness. As new technologies emerge, vaccine adoption rates are expected to rise, contributing to market growth. Continuous investment in vaccine research will further strengthen the country’s immunization programs and disease prevention strategies.
• Growing Awareness of Vaccine-Preventable Diseases: Public awareness campaigns highlight the importance of vaccines in preventing infectious diseases. The South Korean population places strong emphasis on preventive healthcare, supporting higher vaccination rates. Educational initiatives inform individuals about typhoid fever risks and the benefits of immunization. Media platforms, healthcare professionals, and government agencies contribute to spreading vaccine awareness. Increased knowledge about vaccine safety and effectiveness encourages higher immunization rates. As awareness efforts continue, demand for typhoid fever vaccines is expected to rise, reinforcing market growth and improving public health outcomes.
Challenges in the typhoid fever vaccine market in South Korea are:
• Stringent Regulatory Approval Processes: South Korea maintains strict regulatory guidelines for vaccine approval, ensuring high safety and efficacy standards. The lengthy approval process can delay the introduction of new vaccine formulations. Pharmaceutical companies must meet extensive clinical trial requirements before receiving market authorization. Regulatory complexities can slow innovation and limit the availability of advanced vaccines. Although these measures ensure vaccine safety, streamlining approval processes could enhance market responsiveness. Efforts to balance rigorous regulatory oversight with faster approvals will help improve vaccine accessibility and support market growth.
• Low Disease Prevalence and Limited Local Demand: South Korea has a low prevalence of typhoid fever due to strong sanitation standards and clean water access. The reduced risk of disease transmission limits local demand for typhoid vaccines. Immunization efforts focus primarily on travelers and specific high-risk groups. Limited domestic demand may impact pharmaceutical companies profitability in this segment. Vaccine manufacturers may prioritize other infectious disease markets with higher prevalence rates. Encouraging pre-travel vaccination and maintaining strong public health policies will help sustain market demand despite low disease incidence.
• Economic Considerations and Vaccine Cost: Although South Korea has a strong healthcare system, economic factors influence vaccine pricing and accessibility. The cost of newer conjugate vaccines is higher than traditional options, which may impact affordability. Government funding supports vaccination programs, but private healthcare services may have higher costs. Economic downturns can affect healthcare spending, influencing vaccine procurement decisions. Ensuring cost-effective vaccine options and expanding insurance coverage for immunization will help maintain market stability. Addressing economic challenges will be essential to sustaining high vaccination rates and preventing typhoid fever cases.
The typhoid fever vaccine market in South Korea benefits from strong healthcare infrastructure, government immunization policies, and increasing travel-related vaccine demand. Advancements in vaccine technology and rising public awareness further support market growth. However, stringent regulatory approvals, low disease prevalence, and economic factors pose challenges. Addressing these challenges through streamlined regulations, expanded vaccination programs, and cost-effective solutions will enhance vaccine accessibility. Strengthening collaborations between public and private sectors will ensure continued market growth, supporting national disease prevention efforts and maintaining high immunization rates across South Korea.
List of Typhoid Fever Vaccine Market in South Korea Companies
Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. With these strategies typhoid fever vaccine companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the typhoid fever vaccine companies profiled in this report include-
• Company 1
• Company 2
• Company 3
• Company 4
• Company 5
• Company 6
• Company 7
• Company 8
• Company 9
• Company 10
Typhoid Fever Vaccine Market in South Korea by Segment
The study includes a forecast for the typhoid fever vaccine market in South Korea by type, route of administration, and end use.
Typhoid Fever Vaccine Market in South Korea by Type [Analysis by Value from 2018 to 2030]:
• Live Attenuated Vaccine
• Capsular Polysaccharide Vaccine
• Conjugate Vaccine
• Others
Typhoid Fever Vaccine Market in South Korea by Route of Administration [Analysis by Value from 2018 to 2030]:
• Oral
• Injection
Typhoid Fever Vaccine Market in South Korea by End Use [Analysis by Value from 2018 to 2030]:
• Hospitals & Clinics
• Specialty Centers
• Others
Features of the Typhoid Fever Vaccine Market in South Korea
Market Size Estimates: Typhoid fever vaccine in Australia market size estimation in terms of value ($B).
Trend and Forecast Analysis: Market trends and forecasts by various segments.
Segmentation Analysis: Typhoid fever vaccine in Australia market size by type, route of administration, end use in terms of value ($B).
Growth Opportunities: Analysis of growth opportunities in different type, route of administration, end use for the typhoid fever vaccine in Australia.
Strategic Analysis: This includes M&A, new product development, and competitive landscape of the typhoid fever vaccine in Australia.
Analysis of competitive intensity of the industry based on Porter’s Five Forces model.
If you are looking to expand your business in this or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.
FAQ
Q1. What are the major drivers influencing the growth of the typhoid fever vaccine marketing South Korea?
Answer: The major drivers for this market are the rise in the prevalence of typhoid and the growing demand for combined vaccines that offer protection against multiple diseases.
Q2. What are the major segments of the typhoid fever vaccine market in South Korea?
Answer: The future of the typhoid fever vaccine market in South Korea looks promising with opportunities in the hospital & clinic and specialty center markets.
Q3. Which typhoid fever vaccine market segment in South Korea will be the largest in the future?
Answer: Lucintel forecasts that capsular polysaccharide is expected to witness the highest growth over the forecast period due to its efficiency at preventing infection from bacteria, being safe with limited side effects, and it can be administered orally or by injection, making it easy and convenient to use.
Q4. Do we receive customization in this report?
Answer: Yes, Lucintel provides 10% customization without any additional cost.
This report answers following 11 key questions:
Q.1. What are some of the most promising, high-growth opportunities for the typhoid fever vaccine market in South Korea by type (live attenuated vaccine, capsular polysaccharide vaccine, conjugate vaccine, and others), route of administration (oral and injection), and end use (hospitals & clinics, specialty centers, and others)?
Q.2. Which segments will grow at a faster pace and why?
Q.3. Which region will grow at a faster pace and why?
Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
Q.5. What are the business risks and competitive threats in this market?
Q.6. What are the emerging trends in this market and the reasons behind them?
Q.7. What are some of the changing demands of customers in the market?
Q.8. What are the new developments in the market? Which companies are leading these developments?
Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?